Sophie Kervyn

Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action

Richard E Carson, Nabeel Nabulsi, Daniel Holden, 2016, Epilepsia.

A global pharmaceutical company initiative: an evidence-based approach to define the upper limit of body weight loss in short term toxicity studies.

Fiona Sewell, Sally Robinson, Kathryn Chapman, 2013, Regulatory toxicology and pharmacology : RTP.

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.

Sally Robinson, Kathryn Chapman, David Dreher, 2008, Regulatory toxicology and pharmacology : RTP.